Neurotoxic (A1) Reactive Astrocytes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurotoxic (A1) Reactive Astrocytes
Type: Glial Cell
Origin: Resting astrocytes activated by microglial cytokines
Markers: C3, GBP2, SERPING1, complement components
Inducers: IL-1α, TNF-α, C1q from activated microglia
Function: Neurotoxic, promote synapse loss and neuronal death
Disease Association: Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Multiple Sclerosis
Key Reference: [Liddelow et al., 2017](https://doi.org/10.1038/nature21029)
Neurotoxic A1 reactive astrocytes are a distinct subtype of reactive astrocytes that acquire a harmful phenotype in response to specific inflammatory signals from activated microglia. First characterized by Liddelow and colleagues in 2017, these cells lose their normal supportive functions and actively contribute to neurodegeneration by promoting neuronal and oligodendrocyte death 1.
¶ Induction and Activation
A1 astrocyte induction requires simultaneous exposure to three cytokines secreted by activated microglia 1:
- IL-1α — initiates the transcriptional reprogramming
- TNF-α — amplifies inflammatory gene expression
- C1q — initiates complement cascade activation
graph TD
A[Neural injury/insult] --> B[Microglial activation] -->
B --> C[Secretion of IL-1α, TNF-α, C1q] -->
C --> D[Astrocyte receptor engagement] -->
D --> E[NF-κB pathway activation] -->
E --> F[Transcriptional reprogramming] -->
F --> G[A1 reactive phenotype] -->
G --> H[Loss of trophic support] -->
G --> I[Gain of neurotoxic functions] -->
H --> J[Neuronal death] -->
I --> J
| Marker |
Function |
Role in Neurotoxicity |
| C3 (Complement C3) |
Complement component |
Synapse tagging for elimination |
| GBP2 |
Guanylate binding protein |
Inflammatory signaling |
| SERPING1 |
Complement inhibitor |
Dysregulated complement control |
| GGT1 |
Gamma-glutamyltransferase |
Glutathione metabolism |
| AMIGO2 |
Adhesion molecule |
Cell-cell interactions |
A1 astrocytes show reduced expression of genes critical for normal astrocyte function:
- SPARCL1 — synapse formation and maintenance
- GJA1 (Connexin-43) — gap junction communication
- SLC1A2 (GLT-1) — glutamate uptake
- ALDOC — metabolic support
In Alzheimer's disease, A1 astrocytes are prominently found surrounding amyloid-β plaques and neurofibrillary tangles 2. They contribute to disease progression through:
- Complement-mediated synapse loss — C3 deposition on synapses marks them for microglial phagocytosis
- Reduced glutamate clearance — Loss of GLT-1 leads to excitotoxicity
- Secretion of neurotoxic factors — Release of unknown toxic molecules that kill neurons
The presence of A1 astrocytes correlates with disease severity and cognitive decline 3.
In Parkinson's disease, A1 astrocytes are enriched in the substantia nigra and striatum, regions most affected by dopaminergic neuron loss 4. They contribute to:
- Loss of dopaminergic neurons in the SNpc
- Striatal synaptic dysfunction
- Propagation of α-synuclein pathology
ALS patients show extensive A1 astrocyte accumulation in the motor cortex and spinal cord 5. These astrocytes:
- Release toxic factors that kill motor neurons
- Promote motor neuron death through complement activation
- Contribute to disease spreading along motor pathways
In Huntington's disease models, A1 astrocytes appear early in disease progression and contribute to striatal neuron vulnerability 6.
Strategies to prevent A1 astrocyte formation include:
- Anti-cytokine therapies — Blocking IL-1α, TNF-α, or C1q
- Complement inhibition — Targeting C1q or C3 to prevent A1 induction
- NF-κB inhibition — Blocking downstream signaling
Converting A1 to neuroprotective A2 astrocytes may be therapeutic:
- STAT3 activation — Promotes protective astrocyte phenotype
- Growth factor delivery — BDNF, GDNF, CNTF support astrocyte protective functions
Several approaches targeting astrocyte activation are in development:
- Anti-C1q antibodies (ANX005) in clinical trials for ALS
- TNF inhibitors being evaluated for neuroinflammation
- IL-1 receptor antagonists (anakinra) in AD trials
The study of Neurotoxic (A1) Reactive Astrocytes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Liddelow SA, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017;541:481-487. DOI:10.1038/nature21029
- Lian H, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron 2015;85:101-115. DOI:10.1016/j.neuron.2014.11.018
- Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature 2019;571:355-360. DOI:10.1038/s41586-019-0913-4
- Yun SP, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med 2018;24:931-938. DOI:10.1038/s41591-018-0051-5
- Phatnani HN, et al. Intricate interplay between astrocytes and motor neurons in ALS. Nature Neuroscience 2018;21:886-894. DOI:10.1038/s41593-018-0291-9
- Diaz-Amarilla P, et al. M1 microglia promote A1 astrocyte induction in Huntington's disease. J Neurosci 2019;39:3724-3738. DOI:10.1523/JNEUROSCI.0617-19.2019
Last updated: 2026-03-05